On this page
What is Interstitial Nephritis?
Interstitial nephritis is one of the most common causes of acute kidney injury (AKI), which is a sudden and serious deterioration in kidney function. It is characterized by inflammation of the interstitial tissue surrounding the renal tubules, the microscopic structures responsible for filtering waste products and regulating fluid and electrolyte balance. When this surrounding tissue becomes inflamed, the ability of the kidneys to purify the blood and produce urine is significantly impaired.
In the majority of cases, interstitial nephritis is triggered by side effects of medications. These medications are usually taken for entirely unrelated conditions, and patients are often unaware of the connection. If the underlying cause is not identified and addressed promptly, the condition can progress to permanent kidney damage and, in severe cases, chronic kidney failure (renal insufficiency).
Understanding the causes, recognizing the symptoms, and seeking timely medical evaluation are critical steps in preserving kidney function and preventing long-term consequences.
Causes
Interstitial nephritis is classified into two main forms based on its duration and course:
- Acute interstitial nephritis (AIN): the most common form, with a relatively abrupt onset. If the causative factor is removed promptly, there is potential for substantial or even complete recovery of kidney function.
- Chronic interstitial nephritis (CIN): a more insidious form that develops and persists over weeks, months, or even years, with a greater risk of irreversible kidney scarring.
Drug-Induced Interstitial Nephritis
Medications are the most common cause of acute interstitial nephritis across all age groups, accounting for approximately 70–75% of cases. The mechanism is typically an immune-mediated hypersensitivity reaction (not a direct toxic effect), meaning the drug acts as a trigger that provokes the body’s own immune system to attack the kidney’s interstitial tissue.
The classes of drugs most frequently implicated include:
- Antibiotics: particularly penicillins (e.g., ampicillin, amoxicillin), cephalosporins, ciprofloxacin, and rifampicin.
- Non-steroidal anti-inflammatory drugs (NSAIDs): These include common over-the-counter analgesics, such as ibuprofen and naproxen. Because they are so widely used, NSAIDs are among the most frequent culprits.
- Proton pump inhibitors (PPIs): widely prescribed for gastritis, peptic ulcer, and gastroesophageal reflux disease (GERD). GERD, for example, is an increasingly recognized yet often underdiagnosed condition.
- 5-aminosalicylates: used in the management of inflammatory bowel diseases such as ulcerative colitis, proctitis, and Crohn’s disease.
- Allopurinol: prescribed for the management of gout and hyperuricemia.
- Aciclovir: an antiviral agent used in the treatment of herpes virus infections.
- Diuretics (e.g., furosemide, thiazides), anticonvulsants (e.g., phenytoin, carbamazepine), and certain chemotherapy agents have also been implicated.
Important: In theory, virtually any drug has the potential to trigger interstitial nephritis in susceptible individuals. The list of implicated medications has grown steadily over time and continues to expand. Awareness of this risk is essential when prescribing or taking medications, particularly on a long-term basis.
Infection-Related Interstitial Nephritis
Infectious agents can directly invade the renal interstitium or trigger an immune-mediated inflammatory response that damages it. This form is more commonly associated with chronic interstitial nephritis. Responsible pathogens include:
- Bacteria and spirochetes: Escherichia coli (E. coli), Campylobacter (Campylobacter jejuni), Salmonella (Salmonella), streptococci, and spirochetes causing leptospirosis and syphilis
- Viruses: HIV, cytomegalovirus (CMV), Epstein-Barr virus (EBV), measles virus, mumps virus, polyomavirus (such as BK virus, which is particularly relevant in transplant recipients), and herpes simplex virus.
- Parasites: including Toxoplasma gondii (toxoplasmosis) and Leishmania species (leishmaniasis)
- Fungi: including Histoplasma capsulatum (histoplasmosis) and Coccidioides immitis (coccidioidomycosis)
Systemic and Autoimmune Diseases
Several systemic conditions can cause or predispose to chronic interstitial nephritis through immune-mediated mechanisms:
- Sarcoidosis: granulomatous inflammation can directly involve the renal interstitium
- Sjögren’s syndrome: tubulo-interstitial nephritis is one of the most common renal manifestations of this autoimmune condition
- Systemic lupus erythematosus (SLE): lupus nephritis frequently has an interstitial component
- IgG4-related disease: a recently characterized immune-mediated fibroinflammatory condition that can affect multiple organs, including the kidneys
- Anti-GBM disease and ANCA-associated vasculitis: can involve the renal interstitium in their broader disease process
Idiopathic Interstitial Nephritis
In many cases, even after a thorough clinical investigation, no identifiable cause can be established. These cases are classified as idiopathic interstitial nephritis, a diagnosis of exclusion made only after all other potential causes have been carefully evaluated and ruled out.
Symptoms
The clinical presentation of interstitial nephritis is highly variable. Many patients, especially in the early stages, are asymptomatic or experience only vague, non-specific symptoms. These symptoms do not immediately suggest kidney disease.
Latency Period in Drug-Induced Cases
When the cause is a medication, there is typically a latency period between first drug exposure and the clinical onset of kidney dysfunction. This delay is usually several days to a few weeks, though in some cases (particularly with NSAIDs or proton pump inhibitors) it can extend to several months. Notably, if a patient who has previously experienced drug-induced interstitial nephritis is re-exposed to the same medication, the reaction tends to occur much more rapidly. This is due to prior immune sensitization, and in some cases, symptoms may appear within just a few days.
Common Symptoms
The most frequently reported symptoms include:
- Nausea and vomiting
- General malaise and fatigue
- Flank pain (pain in the side or lower back, in the region of the kidneys)
Signs and Symptoms of Allergic Reaction (Drug-Induced AIN)
A classic triad of symptoms has been described in drug-induced AIN, though it is present in fewer than 10–15% of patients:
- Skin rash (maculopapular or morbilliform eruption)
- Low-grade fever
- Eosinophilia (elevated eosinophil count in the blood)
The absence of this triad does not exclude the diagnosis.
Symptoms Reflecting Impaired Kidney Function
As kidney function deteriorates, more specific urinary and systemic signs may emerge:
- Blood in the urine (hematuria): the urine may appear pink, red, or cola-colored.
- Fever (reflecting the underlying inflammatory or infectious process).
- Fatigue or mental confusion (which occurs due to the accumulation of metabolic waste products in the blood, known as uremia).
- Swelling (edema) of the hands (learn more), feet and ankles (learn more), or other body parts. This occurs because of impaired fluid excretion.
- Unexplained weight gain from fluid retention.
- High blood pressure (hypertension): the kidneys play a central role in blood pressure regulation; interstitial inflammation disrupts this function.
- Reduced urine output (oliguria) or, in severe cases, anuria (complete cessation of urine production).
- Electrolyte imbalances: including hyperkalemia (elevated potassium), metabolic acidosis, and hyponatremia.
Key clinical point: Because many of these symptoms are non-specific and overlap with numerous other conditions, interstitial nephritis can be difficult to recognize on clinical grounds alone. A high index of suspicion is essential for timely diagnosis, particularly in patients taking medications known to cause acute interstitial nephritis.
Complications
The most significant risk associated with interstitial nephritis is the development of permanent structural kidney damage, especially if the causative factor isn’t identified and removed in time. This manifests as interstitial fibrosis and tubular atrophy (IFTA): the replacement of functional kidney tissue with scar tissue, which leads to an irreversible and often progressive decline in kidney function, even after the acute episode has resolved.
Depending on the extent of fibrosis, long-term complications may include:
- Chronic kidney disease (CKD): persistent, progressive impairment of renal filtration function
- End-stage renal disease (ESRD): requiring long-term renal replacement therapy (dialysis or kidney transplantation)
- Chronic hypertension: secondary to reduced kidney function and impaired renin-angiotensin-aldosterone regulation
- Renal tubular acidosis: impaired renal acid-base regulation
- Fanconi syndrome: a more generalized form of tubular dysfunction affecting the reabsorption of multiple substances (glucose, amino acids, phosphate, uric acid, potassium, bicarbonate)
Early recognition and prompt intervention are the most effective strategies for minimizing the risk of these long-term consequences.
Diagnosis
Clinical Suspicion
Because interstitial nephritis can present with subtle or non-specific symptoms, clinical suspicion is the essential first step. A physician should consider the diagnosis in any patient presenting with:
- Unexplained decline in kidney function (rising serum creatinine and BUN)
- A history of recent initiation of a potentially causative medication
- Laboratory signs of kidney inflammation, even in the absence of classic symptoms
Urinalysis and Blood Tests
Several laboratory abnormalities may support the diagnosis:
- Sterile pyuria: the presence of white blood cells in the urine without detectable bacteria, which helps rule out a urinary tract infection. This is one of the most characteristic findings.
- Proteinuria: protein leaking into the urine due to tubular dysfunction; typically of low molecular weight (“tubular proteinuria”) rather than the heavy proteinuria seen in glomerulonephritis
- Hematuria: blood in the urine, either visible (gross hematuria) or detectable only on urine dipstick or microscopy
- Urinary eosinophils: while classically associated with drug-induced AIN, this finding has limited sensitivity and specificity and is no longer routinely used as a diagnostic criterion
- Elevated serum creatinine and blood urea nitrogen (BUN): reflecting reduced glomerular filtration rate (GFR)
- Electrolyte disturbances: particularly hyperkalemia and metabolic acidosis
- Peripheral blood eosinophilia: suggests an allergic or immune-mediated mechanism
Imaging
Renal ultrasound is a non-invasive and widely available first-line imaging tool. In interstitial nephritis, it may reveal:
- Normal or enlarged kidneys (in contrast to the shrunken kidneys of chronic disease)
- Increased cortical echogenicity (reflecting inflammation)
- Normal renal vasculature (helping to distinguish AIN from renovascular causes of AKI)
Renal Biopsy: The Gold Standard
While the clinical and laboratory findings can strongly suggest the diagnosis, renal biopsy remains the definitive diagnostic tool for interstitial nephritis. A small core of kidney tissue is obtained under imaging guidance (usually ultrasound) and sent for histological analysis.
Characteristic biopsy findings in AIN include:
- Diffuse or focal interstitial inflammation: predominantly lymphocytes, monocytes, and plasma cells; eosinophils are frequently present in drug-induced AIN
- Tubulitis: inflammatory cells infiltrating the tubular epithelium
- Interstitial edema
- Absence of significant glomerular or vascular changes (distinguishing AIN from glomerulonephritis)
- Granulomatous inflammation: characteristic of sarcoidosis-related and some drug-induced cases
Biopsy is particularly indicated when the diagnosis is uncertain, when the patient fails to respond to initial management, or when distinguishing between different causes of AKI has direct therapeutic implications.
Treatment
The cornerstone of treatment for interstitial nephritis is identifying and eliminating the causative factor. In drug-induced AIN, this means the immediate discontinuation of the offending medication, as continued exposure perpetuates the immune-mediated inflammatory injury.
General Supportive Measures
- Fluid management: careful monitoring and optimization of fluid balance to maintain adequate renal perfusion without causing fluid overload
- Electrolyte correction: prompt treatment of hyperkalemia, metabolic acidosis, and other imbalances
- Blood pressure control: antihypertensive therapy as needed
- Dialysis (renal replacement therapy): in cases of severe acute kidney injury with life-threatening complications (severe hyperkalemia, refractory fluid overload, uremic symptoms), temporary dialysis may be necessary as a bridge while the kidneys recover. In the majority of drug-induced AIN cases, dialysis can be discontinued once kidney function improves.
Immunosuppressive Therapy
Evidence for pharmacological treatment beyond removing the causative agent remains limited and somewhat controversial, and no universally agreed guidelines exist. However, corticosteroids (given orally or intravenously, such as prednisolone or methylprednisolone) are frequently used in clinical practice to:
- Suppress the immune-mediated inflammatory process
- Accelerate recovery of kidney function
- Reduce the risk of progression to permanent fibrosis
Corticosteroid therapy is generally initiated when:
- The diagnosis is confirmed by biopsy
- Kidney function fails to recover promptly after removal of the causative drug
- The interstitial infiltrate is predominantly inflammatory (rather than fibrotic) on biopsy
The duration of steroid therapy is typically 4–12 weeks, with a gradual taper. In steroid-resistant or steroid-dependent cases, other immunosuppressive agents (e.g., mycophenolate mofetil, azathioprine) may be considered.
Management of Chronic Interstitial Nephritis
In the chronic form, treatment must be adapted to the underlying cause (e.g., immunosuppression for autoimmune diseases, antimicrobial therapy for infections, discontinuation of nephrotoxic agents) alongside measures to slow the progression of kidney disease:
- Antihypertensive therapy: in particular, ACE inhibitors or angiotensin receptor blockers (ARBs), which provide additional renoprotective benefits by reducing intraglomerular pressure and proteinuria
- Dietary modifications:
- Low-sodium diet: to help control blood pressure and fluid retention
- Protein restriction: reducing the filtration burden on damaged kidneys; typically recommended when GFR is significantly reduced
- Potassium and phosphate restriction: as dictated by blood levels
End-Stage Renal Disease
If interstitial nephritis progresses to end-stage renal disease (ESRD) despite optimal management, long-term renal replacement therapy will be required. This can take the form of ongoing dialysis, either hemodialysis or peritoneal dialysis, or kidney transplantation. For eligible patients, kidney transplantation remains the preferred treatment, offering the best outcomes in terms of both survival and quality of life.
Sources and Bibliography
- Naik RH, Annamaraju P. Interstitial Nephritis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. Available from PubMed
- American Kidney Fund. Interstitial Nephritis.
- Praga M, González E. Acute interstitial nephritis. Kidney International. 2010;77(11):956–961. DOI: 10.1038/ki.2010.89
- Perazella MA, Rosner MH. Drug-Induced Acute Kidney Injury. Clinical Journal of the American Society of Nephrology. 2022;17(8):1220–1233. DOI: 10.2215/CJN.11491121
- Muriithi AK, Leung N, Valeri AM, et al. Biopsy-proven acute interstitial nephritis, 1993–2011: a case series. American Journal of Kidney Diseases. 2014;64(4):558–566.
- Raghavan R, Eknoyan G. Acute interstitial nephritis: a reappraisal and update. Clinical Nephrology.
